News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,842 Results
Type
Article (13894)
Company Profile (101)
Press Release (252847)
Section
Business (88456)
Career Advice (472)
Deals (15396)
Drug Delivery (68)
Drug Development (36740)
Employer Resources (50)
FDA (6313)
Job Trends (6232)
News (150894)
Policy (14130)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (453)
Accelerated approval (2)
Adcomms (6)
Allergies (32)
Alliances (23341)
ALS (36)
Alzheimer's disease (398)
Antibody-drug conjugate (ADC) (37)
Approvals (6349)
Artificial intelligence (104)
Autoimmune disease (8)
Automation (3)
Bankruptcy (149)
Best Places to Work (4400)
BIOSECURE Act (9)
Biosimilars (55)
Biotechnology (40)
Bladder cancer (19)
Brain cancer (15)
Breast cancer (77)
Cancer (594)
Cardiovascular disease (70)
Career advice (414)
Career pathing (11)
CAR-T (21)
Cell therapy (85)
Cervical cancer (5)
Clinical research (30978)
Collaboration (326)
Compensation (138)
Complete response letters (17)
COVID-19 (768)
CRISPR (19)
C-suite (117)
Cystic fibrosis (35)
Data (606)
Denatured (15)
Depression (9)
Diabetes (77)
Diagnostics (1335)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (55)
Drug pricing (63)
Drug shortages (12)
Duchenne muscular dystrophy (33)
Earnings (32206)
Editorial (12)
Employer branding (4)
Employer resources (44)
Events (37662)
Executive appointments (358)
FDA (6714)
Featured Employer (20)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (205)
Gene editing (37)
Generative AI (8)
Gene therapy (99)
GLP-1 (341)
Government (1310)
Grass and pollen (2)
Guidances (17)
Healthcare (3642)
Huntington's disease (4)
IgA nephropathy (11)
Immunology and inflammation (34)
Indications (12)
Infectious disease (801)
Inflammatory bowel disease (54)
Inflation Reduction Act (6)
Influenza (13)
Intellectual property (45)
Interviews (61)
IPO (5903)
IRA (29)
Job creations (2056)
Job search strategy (378)
Kidney cancer (6)
Labor market (10)
Layoffs (178)
Leadership (3)
Legal (3460)
Liver cancer (19)
Lung cancer (81)
Lymphoma (52)
Machine learning (1)
Management (16)
Manufacturing (144)
MASH (31)
Medical device (1308)
Medtech (1310)
Mergers & acquisitions (9684)
Metabolic disorders (246)
Multiple sclerosis (20)
NASH (14)
Neurodegenerative disease (22)
Neuropsychiatric disorders (6)
Neuroscience (570)
NextGen: Class of 2025 (1623)
Non-profit (638)
Northern California (681)
Now hiring (7)
Obesity (140)
Opinion (119)
Ovarian cancer (21)
Pain (50)
Pancreatic cancer (14)
Parkinson's disease (44)
Partnered (7)
Patents (104)
Patient recruitment (28)
Peanut (10)
People (28984)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8077)
Phase II (13107)
Phase III (11745)
Pipeline (416)
Podcasts (46)
Policy (61)
Postmarket research (1405)
Preclinical (3229)
Press Release (25)
Prostate cancer (44)
Psychedelics (8)
Radiopharmaceuticals (120)
Rare diseases (158)
Real estate (2646)
Recruiting (17)
Regulatory (10140)
Reports (14)
Research institute (571)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (2)
RSV (7)
Schizophrenia (35)
Series A (35)
Series B (11)
Service/supplier (3)
Sickle cell disease (31)
Southern California (698)
Special edition (7)
Spinal muscular atrophy (79)
Sponsored (6)
Startups (1636)
State (2)
Stomach cancer (3)
Supply chain (28)
Tariffs (10)
The Weekly (29)
United States (6943)
Vaccines (151)
Venture capitalists (13)
Webinars (10)
Weight loss (95)
Women's health (8)
Worklife (3)
Date
Today (38)
Last 7 days (269)
Last 30 days (970)
Last 365 days (12102)
2025 (3096)
2024 (12561)
2023 (14338)
2022 (19698)
2021 (20211)
2020 (19209)
2019 (15058)
2018 (11845)
2017 (13968)
2016 (13202)
2015 (15586)
2014 (12488)
2013 (10627)
2012 (11443)
2011 (11984)
2010 (10921)
Location
Africa (315)
Alabama (13)
Alaska (1)
Arizona (54)
Arkansas (3)
Asia (20177)
Australia (2622)
California (1649)
Canada (874)
China (231)
Colorado (67)
Connecticut (65)
Delaware (53)
Europe (39494)
Florida (309)
Georgia (37)
Idaho (11)
Illinois (188)
India (15)
Indiana (128)
Iowa (1)
Japan (86)
Kansas (55)
Kentucky (12)
Louisiana (1)
Maine (2)
Maryland (246)
Massachusetts (1427)
Michigan (49)
Minnesota (90)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (7)
New Hampshire (6)
New Jersey (724)
New Mexico (7)
New York (488)
North Carolina (380)
North Dakota (2)
Northern California (681)
Ohio (49)
Oklahoma (4)
Oregon (16)
Pennsylvania (416)
Puerto Rico (8)
Rhode Island (7)
South America (503)
South Carolina (2)
Southern California (698)
Tennessee (34)
Texas (220)
Utah (34)
Virginia (70)
Washington D.C. (29)
Washington State (112)
Wisconsin (14)
266,842 Results for "concert pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Sun Pharma Completes Acquisition of Concert Pharmaceuticals
Sun Pharmaceutical Industries Limited today announced the successful completion of its acquisition of Concert Pharmaceuticals, Inc.
March 6, 2023
·
6 min read
Business
Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata
Sun Pharmaceutical Industries Limited and Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) (“Concert”) today announced that they have executed a definitive agreement under which Sun Pharma will acquire all outstanding shares of Concert through a tender offer for an upfront payment of $8.00 per share of common stock in cash, or $576 million in equity value.
January 19, 2023
·
16 min read
Business
Concert Pharmaceuticals Reports Third Quarter 2022 Financial Results
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2022.
November 7, 2022
·
9 min read
Genetown
Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata
Concert Pharmaceuticals, Inc. today announced that, after a recent review of deuruxolitinib clinical data by the U.S. Food and Drug Administration (FDA), the FDA determined that deuruxolitinib will maintain its Breakthrough Therapy designation.
February 15, 2023
·
4 min read
Genetown
Concert Pharmaceuticals to Participate in Fireside Chat at the Jefferies London Healthcare Conference
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate in a fireside chat at the Jefferies London Healthcare Conference on November 16, 2022, at 10:20 a.m. GMT.
November 9, 2022
·
1 min read
Business
Concert Pharmaceuticals Reports Second Quarter 2022 Financial Results
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2022.
August 4, 2022
·
10 min read
Business
Concert Pharmaceuticals to Report Third Quarter 2022 Results on November 7, 2022
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the third quarter of 2022, on Monday, November 7, 2022, before the U.S. financial markets open.
October 31, 2022
·
1 min read
Business
Concert Pharmaceuticals Reports First Quarter 2022 Financial Results
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2022.
May 5, 2022
·
8 min read
Genetown
Concert Pharmaceuticals to Present at H.C. Wainwright Annual Global Investment Conference 2022
Concert Pharmaceuticals, Inc. announced that it will participate virtually at the H.C. Wainwright 24th Annual Global Investment Conference, and its presentation will be available beginning at 7:00 a.m. ET on September 12, 2022.
September 6, 2022
·
1 min read
Business
Concert Pharmaceuticals to Report Second Quarter 2022 Results on August 4, 2022
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the second quarter of 2022, on Thursday, August 4, 2022, before the U.S. financial markets open.
July 29, 2022
·
1 min read
1 of 26,685
Next
